SLC27A4 and hepatocellular carcinoma: 2023; Hasmann and Schemainda 2003), in blocking sEV‐NAMPT as a treatment option in various animal models. In addition, FK866 inhibited the sEV‐NAMPT‐SLC27A4 pathway because a reduced TG concentration was observed in the treatment group. These findings suggest the possibility of targeting sEV‐NAMPT as a promising therapeutic strategy for HCC patients. Although FK866 had a positive outcome in our study, we are aware that phase II clinical trials of cutaneous T‐cell lymphoma have failed because of its high toxicity (Wei and Zhang 2022).